Show simple item record

dc.contributor.authorCastellano, Daniel
dc.contributor.authorGonzález-Larriba, José L.
dc.contributor.authorAntón-Aparicio, Luis M.
dc.contributor.authorCassinello, Javier
dc.contributor.authorGrande-Pulido, E.
dc.contributor.authorEsteban, Emilio
dc.contributor.authorSepúlveda, Juan
dc.description.abstractObjective: Vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) correlate with poor prognosis in castration-resistant prostate cancer (CRPC). Sunitinib has shown activity in CRPC and at the time of this analysis there was no standard therapy for docetaxel-refractory CRPC. Methods: We present a case series data collection of 19 patients with a median age of 73 years, CRPC and rising prostate-specific antigen (PSA). Patients received sunitinib 37.5 mg continuous daily dose. One cycle comprised a 4-week period. Patients were evaluated by CT scan every 8 weeks and PSA was monitored every 4 weeks. Results: Median Eastern Cooperative Oncology Group (ECOG) performance status score was 2. Patients received a median of two previous treatment lines for the hormone-refractory setting. Baseline median PSA was 280 ng/ml. Patients received a median of 16 weeks of therapy (4 – 48+). One patient achieved a partial response (5%) and 12 (66.7%) achieved stable disease for at least 3 months according to RECIST criteria. Median progression-free survival was 4 months. PSA declined > 50% in 5/19 (26.3%) and stabilized in 7/19 (37%) patients. Frequent adverse events were grade 3 asthenia (21%), grade 3 diarrhea (10%) and grade 3 hand-foot syndrome (15.7%). Conclusions: Activity with sunitinib was observed in highly pretreated docetaxel-refractory CRPC with acceptable tolerability. Additional studies should confirm the role of antiangiogenic agents in this
dc.publisherExpert Opinion on Pharmacotherapyspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectDaily practicespa
dc.subjectProstate cancerspa
dc.titleExperience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer
dc.typejournal articlespa
dc.rights.accessRightsmetadata only accessspa
dc.description.extent2,43 MBspa

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España